Patents by Inventor Jooho Shin
Jooho Shin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200315989Abstract: A method of increasing PGC-1? gene expression, decreasing PARIS gene expression, or promoting farnesylation of PARIS in a mammalian cell, the method comprising administering an effective amount of farnesol, a pharmaceutically acceptable salt thereof, or a solvate thereof to the cell; and related methods and compositions.Type: ApplicationFiled: June 24, 2020Publication date: October 8, 2020Inventors: Sungchun CHO, Kyungho KIM, Euiseok SHIN, Jongsun KANG, Jooho SHIN, Juhyeon BAE, Hyeonju JEONG, Areum JO, Sangchul PARK
-
Patent number: 10780061Abstract: A method of increasing PGC-1? gene expression, decreasing PARIS gene expression, or promoting farnesylation of PARIS in a mammalian cell, the method comprising administering an effective amount of farnesol, a pharmaceutically acceptable salt thereof, or a solvate thereof to the cell; and related methods and compositions.Type: GrantFiled: September 25, 2015Date of Patent: September 22, 2020Assignee: DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Sungchun Cho, Kyungho Kim, Euiseok Shin, Jongsun Kang, Jooho Shin, Juhyeon Bae, Hyeonju Jeong, Areum Jo, Sangchul Park
-
Publication number: 20170157145Abstract: A method of inducing Parkin expression; inhibiting oxidative stress; and inhibiting cell death of cells by administering deferasirox, hydrocortisone, ketorolac, dexamethasone, and prednisone, a pharmaceutically acceptable salt, stereoisomer, derivative, or solvate thereof to the cell, optionally in a subject, as well as a method of preventing or treating neurodegenerative disease in the subject.Type: ApplicationFiled: October 24, 2016Publication date: June 8, 2017Inventors: Yunil Lee, Yunjong Lee, Sangwoo Ham, Sangchul Park, Jooho Shin
-
Publication number: 20160089340Abstract: A method of increasing PGC-1? gene expression, decreasing PARIS gene expression, or promoting farnesylation of PARIS in a mammalian cell, the method comprising administering an effective amount of farnesol, a pharmaceutically acceptable salt thereof, or a solvate thereof to the cell; and related methods and compositions.Type: ApplicationFiled: September 25, 2015Publication date: March 31, 2016Inventors: Sungchun Cho, Kyungho Kim, Euiseok Shin, Jongsun Kang, Jooho Shin, Juhyeon Bae, Hyeonju Jeong, Areum Jo, Sangchul Park
-
Patent number: 9274128Abstract: Parkinson's disease is caused by the preferential loss of substantia nigra dopamine neurons. A Parkin Interacting Substrate, PARIS (ZNF746) is identified. The levels of PARIS are regulated by the ubiquitin proteasome system via binding to and ubiquitination by the E3 ubiquitin ligase, parkin. PARIS is a KRAB and zinc finger protein that accumulates in models of parkin inactivation and in human brain Parkinson's disease patients. PARIS represses the expression of the transcriptional co-activator, PGC-1? and the PGC-1? target gene, NRF-1 by binding to insulin response sequences in the PGC-1? promoter. Conditional knockout of parkin in adult animals leads to progressive loss of dopamine (DA) neurons that is PARIS dependent. Overexpression of PARIS causes selective loss of DA neurons in the substantia nigra, which is reversed by either parkin or PGC-1? co-expression. The identification of PARIS provides a molecular mechanism for neurodegeneration due to parkin inactivation.Type: GrantFiled: September 12, 2014Date of Patent: March 1, 2016Assignee: VALTED, LLCInventors: Ted M. Dawson, Valina L. Dawson, Han Seok Ko, Jooho Shin
-
Patent number: 8921042Abstract: Parkinson's disease is caused by the preferential loss of substantia nigra dopamine neurons. A Parkin Interacting Substrate, PARIS (ZNF746) is identified. The levels of PARIS are regulated by the ubiquitin proteasome system via binding to and ubiquitination by the E3 ubiquitin ligase, parkin. PARIS is a KRAB and zinc finger protein that accumulates in models of parkin inactivation and in human brain Parkinson's disease patients. PARIS represses the expression of the transcriptional co-activator, PGC-1? and the PGC-1? target gene, NRF-1 by binding to insulin response sequences in the PGC-1? promoter. Conditional knockout of parkin in adult animals leads to progressive loss of dopamine (DA) neurons that is PARIS dependent. Overexpression of PARIS causes selective loss of DA neurons in the substantia nigra, which is reversed by either parkin or PGC-1? co-expression. The identification of PARIS provides a molecular mechanism for neurodegeneration due to parkin inactivation.Type: GrantFiled: October 17, 2013Date of Patent: December 30, 2014Assignee: Valted LLCInventors: Ted M. Dawson, Valina L. Dawson, Han Seok Ko, Jooho Shin
-
Publication number: 20140378536Abstract: Parkinson's disease is caused by the preferential loss of substantia nigra dopamine neurons. A Parkin Interacting Substrate, PARIS (ZNF746) is identified. The levels of PARIS are regulated by the ubiquitin proteasome system via binding to and ubiquitination by the E3 ubiquitin ligase, parkin. PARIS is a KRAB and zinc finger protein that accumulates in models of parkin inactivation and in human brain Parkinson's disease patients. PARIS represses the expression of the transcriptional co-activator, PGC-1? and the PGC-1? target gene, NRF-1 by binding to insulin response sequences in the PGC-1? promoter. Conditional knockout of parkin in adult animals leads to progressive loss of dopamine (DA) neurons that is PARIS dependent. Overexpression of PARIS causes selective loss of DA neurons in the substantia nigra, which is reversed by either parkin or PGC-1? co-expression. The identification of PARIS provides a molecular mechanism for neurodegeneration due to parkin inactivation.Type: ApplicationFiled: September 12, 2014Publication date: December 25, 2014Applicant: VALTED, LLCInventors: Ted M. Dawson, Valina L. Dawson, Han Seok Ko, Jooho Shin
-
Publication number: 20140045921Abstract: Parkinson's disease is caused by the preferential loss of substantia nigra dopamine neurons. A Parkin Interacting Substrate, PARIS (ZNF746) is identified. The levels of PARIS are regulated by the ubiquitin proteasome system via binding to and ubiquitination by the E3 ubiquitin ligase, parkin. PARIS is a KRAB and zinc finger protein that accumulates in models of parkin inactivation and in human brain Parkinson's disease patients. PARIS represses the expression of the transcriptional co-activator, PGC-1? and the PGC-1? target gene, NRF-1 by binding to insulin response sequences in the PGC-1? promoter. Conditional knockout of parkin in adult animals leads to progressive loss of dopamine (DA) neurons that is PARIS dependent. Overexpression of PARIS causes selective loss of DA neurons in the substantia nigra, which is reversed by either parkin or PGC-1? co-expression. The identification of PARIS provides a molecular mechanism for neurodegeneration due to parkin inactivation.Type: ApplicationFiled: October 17, 2013Publication date: February 13, 2014Applicant: VALTED, LLCInventors: Ted M. Dawson, Valina L. Dawson, Han Seok Ko, Jooho Shin
-
Patent number: 8603994Abstract: Parkinson's disease is caused by the preferential loss of substantia nigra dopamine neurons. A Parkin Interacting Substrate, PARIS (ZNF746) is identified. The levels of PARIS are regulated by the ubiquitin proteasome system via binding to and ubiquitination by the E3 ubiquitin ligase, parkin. PARIS is a KRAB and zinc finger protein that accumulates in models of parkin inactivation and in human brain Parkinson's disease patients. PARIS represses the expression of the transcriptional co-activator, PGC-1? and the PGC-1? target gene, NRF-1 by binding to insulin response sequences in the PGC-1? promoter. Conditional knockout of parkin in adult animals leads to progressive loss of dopamine (DA) neurons that is PARIS dependent. Overexpression of PARIS causes selective loss of DA neurons in the substantia nigra, which is reversed by either parkin or PGC-1? co-expression. The identification of PARIS provides a molecular mechanism for neurodegeneration due to parkin inactivation.Type: GrantFiled: November 11, 2011Date of Patent: December 10, 2013Assignee: Valted, LLCInventors: Ted M. Dawson, Valina L. Dawson, Han Seok Ko, Jooho Shin
-
Publication number: 20120122958Abstract: Parkinson's disease is caused by the preferential loss of substantia nigra dopamine neurons. A Parkin Interacting Substrate, PARIS (ZNF746) is identified. The levels of PARIS are regulated by the ubiquitin proteasome system via binding to and ubiquitination by the E3 ubiquitin ligase, parkin. PARIS is a KRAB and zinc finger protein that accumulates in models of parkin inactivation and in human brain Parkinson's disease patients. PARIS represses the expression of the transcriptional co-activator, PGC-1? and the PGC-1? target gene, NRF-1 by binding to insulin response sequences in the PGC-1? promoter. Conditional knockout of parkin in adult animals leads to progressive loss of dopamine (DA) neurons that is PARIS dependent. Overexpression of PARIS causes selective loss of DA neurons in the substantia nigra, which is reversed by either parkin or PGC-1? co-expression. The identification of PARIS provides a molecular mechanism for neurodegeneration due to parkin inactivation.Type: ApplicationFiled: November 11, 2011Publication date: May 17, 2012Inventors: Ted M. Dawson, Valina L. Dawson, Han Seok Ko, Jooho Shin